Tenacity, creativity and adaptability – these are the qualities that a CEO should embody to become a titan in their industry. Bringing in these qualities to the emerging microbiome industry, Martha Carlin leads The BioCollective, a unique business that invests in both consumer products and microbiological research. Driven by a passion to give people the tools to take control of their health, the BioCollective team leverages some of the most advanced expertise in microbial ecology to tap the massive potential of microbiota in promoting human health. Because of her inspiring leadership, she has won her rightful place among the 2020 Titan 100. She graces the podcast on this co-hosted episode with Bob Roark and his co-host, Jaime Zawmon, President of TITAN CEO.

---

Watch the episode here:

[embed]https://youtu.be/0bXNCv6gpMM[/embed]

Leading With Tenacity, Creativity And Adaptability With Guest, Martha Carlin Of The BioCollective And Co-host, Jaime Zawmon Of TITAN CEO

We have quite the treat. We have a Jaime Zawmon. She is the Founder and President of Titan CEO. We have Martha Carlin. She is the CEO and Cofounder of The BioCollective. We're having a co-hosted episode. Martha, Jaime, thank you so much for being on the show.

Thank you for having me.

Martha, thank you and congrats on being selected to the Titan 100, a big honor.

I’m very excited about it.

 

Martha, tell us about your business and who you serve.

My business is unique. It's in the field of the microbiome. For people who may not know what the microbiome is, it's the trillions of bacteria, fungi and viruses that live in and on our body. Over the last years, it's become increasingly apparent that the bacteria that live in and on our body are a critical component to our health. I recognize this after reading a book called Missing Microbes back in 2014, founded The BioCollective in 2015 to try to accelerate the path to discovery and helping people get healthier. By doing that, we went into an industry that most people had never heard of. It was rapidly growing and expanding. When I started the company, there were about twenty microbiome companies worldwide, and now there are thousands and thousands, but it's still pretty early days.

Our company has evolved in the ways that we are serving two different customer bases. We serve the scientific research community through tools that we developed for our own work to build out a bio-bank of fecal samples and genomic data so that we could start to use artificial intelligence and machine learning to identify patterns in healthy people and diseased people. Through the tools that we developed, we received an NIH grant for $1.2 million to develop one of those quality control and research tools. The division of the BioCollective that has all these research tools is serving the scientific community, the nutrition community, pharmaceutical companies, and big food and big ag to some extent. Along the way, we developed our expertise and brought in a chief scientific officer with over 30 years of microbial ecology and developed a...